Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1568-1569, 2007; 10.1373/clinchem.2007.093633
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, H. H.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, H. H.-J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2007;53:1568-1569.)
© 2007 American Association for Clinical Chemistry, Inc.

Editorials

Introducing Single-Nucleotide Polymorphism Markers in the Diagnosis of Wilson Disease

Harmut H.-J. Schmidt

Transplant Hepatology, Domagkstrasse 3A, Munster, Germany, Fax 49-251-835, E-mail hepar@ukmuenster.de

The first 20% of the full text of this article appears below.

Wilson disease (WD) represents a monogenic disease resulting in copper accumulation within tissues. Incidence is estimated to be approximately 1:30 000. Symptoms include acute and chronic liver disease, hemolysis, and neurodegenerative and psychiatric symptoms (1). The first symptom may be acute liver failure. Death or liver transplantation in WD is common. The European Liver Transplant Registry recorded 706 liver transplantations for WD from 1 January 1988 to 31 December 2005, underlining the relevance of this disease burden. Because symptoms and disease course are variable, diagnosis can be difficult. Effective treatment for WD such as copper chelating drugs and zinc is available, which usually prevents disease progression. Therefore, a simple, rapid and diagnostic test is required for WD, ideally to identify patients before symptoms appear. First symptoms have been reported in patients as young as 2 years of age (2)(3). Thus screening tests for WD at least at the age of 2 years would be appropriate. Penetrance of . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.